Sign Up
Stories
CARMAT's 2024 Financial Calendar and Heart Failure Solution
Share
BiVACOR Appoints New Chairman
Evolut TAVR Triumphs in SMART Trial
FDA Breakthrough Device Designation for ...
AI-Powered Raspberry Pi Stethoscope Inno...
BiVACOR Welcomes New CEO and FDA Approva...
CARMAT's Advancements in Artificial Hear...
Overview
API
CARMAT, a French MedTech company, has unveiled its 2024 financial calendar and its mission to offer an alternative to heart transplants through its Aeson® artificial heart. The Aeson® is already commercially available in the EU and under evaluation in the US, while being listed on the Euronext Growth market in Paris.
Ask a question
How could CARMAT's success in providing heart failure solutions influence the broader healthcare landscape and patient care?
How might CARMAT's innovative artificial heart impact the traditional heart transplant industry?
What challenges or considerations might arise in the widespread adoption of the Aeson® artificial heart?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage